Blocking SREBP1-PCSK9 Lipid Pathway Breaks Pancreatic Cancer's Immune Shield
A new study reveals how pancreatic cancer hijacks lipid metabolism to evade immunity—and how targeting SREBP1-PCSK9 reverses this resistance.
Summary
Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to immunotherapy. Researchers at Zhejiang University discovered that the lipid metabolism regulator SREBP1 drives immune evasion in PDAC by directly suppressing PD-L1 transcription while simultaneously activating PCSK9, which stabilizes PD-L1 through lysosomal degradation pathways. Patients responding to anti-PD-1 therapy had significantly lower serum lipid levels than non-responders. Targeting SREBP1 and combining PCSK9-neutralizing antibodies with PD-1 blockade produced robust anti-tumor responses in humanized patient-derived xenograft models and spontaneous genetically engineered mouse models, suggesting a clinically actionable strategy to sensitize pancreatic cancer to immunochemotherapy.
Detailed Summary
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with a 5-year survival rate below 12%. Immune checkpoint blockade (ICB), transformative in many cancers, has largely failed in PDAC due to its profoundly immunosuppressive tumor microenvironment (TME). A key but underexplored driver of this immunosuppression is the cancer's aberrant lipid metabolism. This study from Zhejiang University systematically dissected how SREBP1, a master transcriptional regulator of lipid synthesis, orchestrates immune evasion in PDAC.
The researchers first established clinical relevance: in a Chinese PDAC cohort and TCGA datasets, high SREBP1 expression correlated with poor prognosis. Critically, patients who responded to anti-PD-1 therapy showed markedly lower serum lipid levels (total cholesterol, LDL, triglycerides) compared to non-responders, suggesting lipid metabolism status predicts immunotherapy response. High-fat diet mouse models confirmed that elevated lipid availability accelerated tumor growth and worsened immune exclusion.
Mechanistically, the study revealed a dual regulatory node. First, SREBP1 directly binds the PD-L1 (CD274) promoter and paradoxically suppresses its transcription—an unexpected finding given that high SREBP1 activity correlates with greater immune evasion. Second, SREBP1 transcriptionally activates PCSK9, the proprotein convertase previously known for its cardiovascular role in LDL receptor degradation. In PDAC, PCSK9 was found to stabilize PD-L1 protein by blocking lysosomal degradation, thereby elevating surface PD-L1 and suppressing anti-tumor T-cell activity. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays confirmed direct SREBP1 binding to the PCSK9 promoter, while bafilomycin-A1 (lysosomal inhibitor) experiments validated the lysosomal PD-L1 degradation mechanism.
In vivo, combining PCSK9-neutralizing antibodies with anti-PD-1 therapy produced synergistic anti-tumor effects. Testing across PDAC-bearing syngeneic mice, humanized patient-derived xenograft (PDX) models, and the GEMM-KTC spontaneous PDAC model (LSL-KrasG12D/+; TgfbRfl/+; Ptf1a-cre) demonstrated significant tumor regression, increased CD8+ T-cell infiltration, elevated granzyme B expression, and reduced Foxp3+ regulatory T cells—collectively indicating restored anti-tumor immunity. Adding gemcitabine to the regimen further enhanced efficacy in the triple-combination arm.
These findings position the SREBP1-PCSK9 axis as a druggable lipid-immune crosstalk pathway. PCSK9-neutralizing monoclonal antibodies are already FDA-approved for cardiovascular disease (evolocumab, alirocumab), offering a potentially rapid translational path. The study suggests that serum lipid profiling could serve as a non-invasive biomarker for predicting anti-PD-1 responsiveness in PDAC patients, and that repurposing PCSK9 inhibitors in combination with ICB warrants urgent clinical investigation.
Key Findings
- PDAC patients responding to anti-PD-1 had significantly lower serum LDL and total cholesterol than non-responders.
- SREBP1 directly suppresses PD-L1 transcription but activates PCSK9, which stabilizes PD-L1 protein via lysosomal blockade.
- PCSK9-neutralizing antibodies combined with anti-PD-1 drove tumor regression in humanized PDX and spontaneous GEMM-KTC mouse models.
- High-fat diet accelerated PDAC growth and deepened immune exclusion in murine models, validating the lipid-immune axis.
- Triple combination of PCSK9 inhibitor, anti-PD-1, and gemcitabine showed the strongest antitumor efficacy across models.
Methodology
The study combined clinical cohort analysis (Chinese PDAC patients and TCGA), mechanistic in vitro assays (ChIP, luciferase reporters, flow cytometry, Western blotting, Co-IP), and multiple in vivo models including syngeneic mouse tumors, humanized PDX models, and spontaneous GEMM-KTC autochthonous pancreatic cancer mice. Serum metabolomics via LC-MS and GC-MS was used to profile lipid changes in responders vs. non-responders.
Study Limitations
The study relies heavily on mouse models; direct human clinical trial data for the PCSK9 inhibitor plus anti-PD-1 combination in PDAC is lacking. The dual and seemingly contradictory role of SREBP1 in suppressing PD-L1 transcription while promoting PCSK9-mediated PD-L1 protein stabilization requires further mechanistic clarification. Long-term safety and efficacy of the triple combination in humans remains untested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.